Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #COVIDDiagnostics--Applied DNA veterinary COVID-19 vaccine induces NAbs against B.1.1.7, P1, and B.1.526 variants; Set launch of mink challenge trial for August.

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, P1, and B.1.526 Variants and Sets August 2021 Mink Challenge Trial Launch

Aurora Cannabis

Arena Pharmaceuticals

Canopy Growth

HEXO Corp

FSD Pharma

Neptune Wellness Solutions Inc.

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Breaking Down a Busy Week of Weed Stocks

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--The acquisition of safeCircle's newest client reflects the service's focus on profitable niche markets and the re-opening of venues for new sales.

Applied DNA Adds First Summer Camp for safeCircle Pooled COVID-19 Surveillance Testing

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Completes Technical Validation of SARS-CoV-2 Mutation Detection Panel; Developing Mutation that Characterizes Indian Variant.

Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation-Detection Panel, Highlights Ability to Rapidly Identify Mutations and Probable Variants

Cara Therapeutics

Corbus Pharmaceuticals Holdings

Flora Growth Corp

GrowGeneration Corp

Akerna Corp

Village Farms International

Zynerba Pharmaceuticals

Here Are the Cannabis Stocks That Caught Fire This Week

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2021 Results - Earnings Call Transcript

STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), today clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit (the “Assay Kit”) and certain information contained in its previously disseminated 12 May 2021 press release (the “Press Release”) relating to the U.S. Food and Drug Administration's (FDA) grant of a re-issued Emergency Use Authorization (EUA) that expands the Assa

Applied DNA Provides Clarification on Newly Authorized Asymptomatic Serial Screening Indication for LineaTM COVID-19 Assay Kit and Press Release Published 12 May 2021

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the three and six months ended March 31, 2021. “We are pleased to deliver a strong fiscal second quarter with year-over-year revenue growth of 384%, capping an impressive first half of the fiscal year distinguished by demand for our COVID-19 diagnostics and surveillance testing offer

Applied DNA Second Fiscal Quarter 2021 Financial Results Feature 384% Year-Over-Year Growth in Revenues

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Linea™ COVID-19 Assay Kit EUA expanded to include asymptomatic serial screening as an expansion of intended use.

FDA Grants EUA to Applied DNA LineaTM COVID-19 Assay Kit for Asymptomatic Screening of Individuals with Serial Testing

The stock price of Applied DNA Sciences Inc (NASDAQ: APDN) increased by over 25% during intraday trading. This is why it happened.

APDN Stock: Over 25% Increase Intraday Explanation

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Applied DNA Clinical Labs, LLC (ADCL) subsidiary received CLIA (Clinical Laboratory Improvement Amendments) certification from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for COVID-19 testing using EUA-authorized methods and devices. With this certifica

Applied DNA Receives CLIA Certification, Enabling High Throughput Diagnostic COVID-19 Testing

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar'

Applied DNA Schedules Fiscal 2021 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 13, 2021

Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Applied DNA Sciences (APDN) Report Negative Q2 Earnings? What You Should Know

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #COVID19Vaccine--Testing showed that neutralizing titers were detected in feline sera with a geometric mean titer for the cohort of 398.

Applied DNA and Evvivax Announce that LinearDNA™ COVID-19 Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines

Supply chain security provider Applied DNA Sciences, Inc. (NASDAQ:APDN) reported Wednesday it had signed a new contract with the Defense Logistics Agency's (DLA) Land and Maritime's Product Test Center (PTC) with a maximal value of $1.04 million. The indefinite-delivery contract has a five-year performance term.

Applied DNA Shares Slightly Up On New Contract With U.S. Defense Logistics Agency

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #DLA--New contract with U.S. Defense Logistics Agency continues support of counterfeit mitigation program running since 2014.

Applied DNA Signs New Contract with U.S. Defense Logistics Agency

Applied DNA Sciences (APDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Applied DNA Sciences (APDN)

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA secures amendment doubling maximal value of MSA and receives 4th purchase order from current COVID-19 Assay Kit customer.

Applied DNA Secures Amendment to Master Services Agreement and Fourth Blanket Purchase Order from Linea™ COVID-19 Assay Kit Customer

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA provides preliminary estimated FQ2'21 revenue range of $2.5 million to $2.7 million and business update.

Applied DNA Provides Preliminary Estimated Fiscal Second Quarter 2021 Revenue Range and Business Update

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #CatHealth--Preliminary results of phase I clinical trial yields high titers of SARS-CoV-2 neutralizing antibodies from all cohort members.

Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA™ COVID-19 Vaccine Candidate in Felines

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #Cotton--Applied DNA CEO discusses relevance of DNA-based cotton traceability in textile manufacturing in interview with BBC.

Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

Applied DNA Sciences (APDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Applied DNA Sciences (APDN) Moves 13.2% Higher: Will This Strength Last?

Applied DNA Sciences (APDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Applied DNA Sciences (APDN) Upgraded to Buy: Here's What You Should Know

STONY BROOK & NEW HYDE PARK, N.Y.--(BUSINESS WIRE)---- $APDN #GenomicSurveillance--Applied DNA and Northwell establish a real-time surveillance program to track and identify SARS-CoV-2 mutations and variants of concern.

Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #ChiefLegalOfficer--Clay Shorrock rejoins the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Exec. Dir., B. Dev.

News for Applied DNA Sciences Stock (APDN)